Thomas Needham

Tom Needham, MBA, is a Director and Head of the Biopharmaceuticals practice at Broadview Ventures.

Tom shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement.

Tom comes to Broadview with 25 years of experience in venture capital, business development, corporate strategy, and executive management responsibilities in public and private life science companies. Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (Nasdaq: MACK) and Senior Vice President, Business Development at C4 Therapeutics.

Prior to C4T, Tom spent 13 years as a venture capital investor, most recently as a Managing Director at Synthesis Capital, where he was involved in the management of two healthcare venture funds focused on investments in biotechnology, pharmaceuticals and medical technology. Prior to Synthesis, Tom was a Principal at Advent International, a global private equity firm, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, including GPC Biotech (FSE: GPC/Nasdaq: GPCB) and Mitotix, Inc. (acquired by GPC Biotech), where he led the negotiation and closing of a number of strategic transactions, including industry partnerships with global pharmaceutical companies, R&D collaborations, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.

Tom currently holds board roles at Renovacor (Chairman), Basking Biosciences (Chairman), Antag Therapeutics, Kantum Pharma (Observer), and HAYA Therapeutics (Observer). Tom’s venture investment experience also includes working on Epirium Bio (fka Cardero Therapeutics), Astex Pharmaceuticals (Nasdaq: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (Nasdaq: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and as an active deal team member on the IPO and exit from Aegerion Pharmaceuticals (Nasdaq: AEGR).